Ayyappa Duba
Rheumatology · Lovington, NMNPI 1487909719
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 294 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 43.7% of the total.
Across 294 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Johnson & Johnson$234
- Pfizer$223
- Lilly USA, LLC$188
- UCB, Inc.$167
- plus $736 from 10 others
What the payments were for
- Speaking & faculty fees$611%
- Food & beverage$4,55196%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 151 | $2,064 |
| Amgen(2 entities) | 66 | $1,108 |
| Johnson & Johnson | 10 | $234 |
| Pfizer | 14 | $223 |
| Lilly USA, LLC | 9 | $188 |
| UCB, Inc. | 8 | $167 |
| GSK | 8 | $139 |
| AstraZeneca | 7 | $131 |
| Fresenius Kabi USA, LLC | 6 | $118 |
| Pacira Therapeutics, Inc. | 2 | $75 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Novartis | 3 | $53 |
| Sanofi | 2 | $51 |
| Boehringer Ingelheim | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
How this compares
$4,720 in reported general payments places this provider in the 70th percentile of 44 rheumatology providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 109 | $858,457 |
| RinvoqUpadacitinib | 100 | $660,659 |
| Enbrel SureclickEtanercept | 52 | $422,001 |
| Enbrel MiniEtanercept | 42 | $326,335 |
| StelaraUstekinumab | 12 | $219,205 |
| KevzaraSarilumab | 41 | $177,651 |
| SimponiGolimumab | 25 | $156,946 |
| Xeljanz XrTofacitinib Citrate | 24 | $154,252 |
| OtezlaApremilast | 21 | $104,535 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 12 | $90,505 |
| Humira(Cf)Adalimumab | 12 | $81,738 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $78,201 |
| OlumiantBaricitinib | 19 | $56,617 |
| Hydroxychloroquine Sulfate | 864 | $23,820 |
| Leflunomide | 218 | $7,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,064 | $742,397112 claims |
| Johnson & JohnsonStelara, Simponi | $234 | $376,15237 claims |
| SanofiKevzara | $51 | $177,65141 claims |
| AmgenOtezla | $1,108 | $104,53521 claims |
| Lilly USA, LLCOlumiant | $188 | $56,61719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Lovington
- Hillary NortonSanta Fe$1.9M
- Ahmad RamahiRoswell$35K
- Adrian Michaella Mesilla$16K
- Wilmer SibbittAlbuquerque$9K
- Arthur SnyderLas Cruces$9K
- Leroy PachecoAlbuquerque$8K
- Albert RizzoliAlbuquerque$7K
- Susan BarrettSanta Fe$7K
- Jayashree SinhaClovis$7K
- Scott StoernerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.